AAAAAA

   
Results: 1-17 |
Results: 17
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies
Authors: Gilbert, J Baker, SD Bowling, MK Grochow, L Figg, WD Zabelina, Y Donehower, RC Carducci, MA
Citation: J. Gilbert et al., A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies, CLIN CANC R, 7(8), 2001, pp. 2292-2300
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
Authors: Gore, SD Weng, LJ Zhai, S Figg, WD Donehower, RC Dover, GJ Grever, M Griffin, CA Grochow, LB Rowinsky, EK Zabalena, Y Hawkins, EK Burks, K Miller, CB
Citation: Sd. Gore et al., Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia, CLIN CANC R, 7(8), 2001, pp. 2330-2339
A phase I clinical and pharmacological evaluation of sodium phenylbutyrateon an 120-h infusion schedule
Authors: Carducci, MA Gilbert, J Bowling, MK Noe, D Eisenberger, MA Sinibaldi, V Zabelina, Y Chen, TL Grochow, LB Donehower, RC
Citation: Ma. Carducci et al., A phase I clinical and pharmacological evaluation of sodium phenylbutyrateon an 120-h infusion schedule, CLIN CANC R, 7(10), 2001, pp. 3047-3055
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immuneactivation
Authors: Jaffee, EM Hruban, RH Biedrzycki, B Laheru, D Schepers, K Sauter, PR Goemann, M Coleman, J Grochow, L Donehower, RC Lillemoe, KD O'Reilly, S Abrams, RA Pardoll, DM Cameron, JL Yeo, CJ
Citation: Em. Jaffee et al., Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immuneactivation, J CL ONCOL, 19(1), 2001, pp. 145-156
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors
Authors: Heath, EI O'Reilly, S Humphrey, R Sundaresan, P Donehower, RC Sartorius, S Kennedy, MJ Armstrong, DK Carducci, MA Sorensen, JM Kumor, K Kennedy, S Grochow, LB
Citation: Ei. Heath et al., Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors, CANC CHEMOT, 48(4), 2001, pp. 269-274
Bioavailablility of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine
Authors: O'Reilly, S Hartman, NR Bowling, KM Rowinsky, EK Donehower, RC Collins, J Strong, JM
Citation: S. O'Reilly et al., Bioavailablility of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine, CANC CHEMOT, 48(3), 2001, pp. 223-228
Tumor targeting by conjugation of DHA to paclitaxel
Authors: Bradley, MO Swindell, CS Anthony, FH Witman, PA Devanesan, P Webb, NL Baker, SD Wolff, AC Donehower, RC
Citation: Mo. Bradley et al., Tumor targeting by conjugation of DHA to paclitaxel, J CONTR REL, 74(1-3), 2001, pp. 233-236
Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma
Authors: Lakhanpal, S Donehower, RC Rowinsky, EK
Citation: S. Lakhanpal et al., Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma, INV NEW DR, 19(1), 2001, pp. 69-76
A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors
Authors: Dees, EC Whitfield, LR Grove, WR Rummel, S Grochow, LB Donehower, RC
Citation: Ec. Dees et al., A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors, CLIN CANC R, 6(10), 2000, pp. 3885-3894
Role of oral chemotherapy in colorectal cancer
Authors: Donehower, RC
Citation: Rc. Donehower, Role of oral chemotherapy in colorectal cancer, ONCOLOGY-NY, 14(11A), 2000, pp. 243-245
A prospective pharmacologic evaluation of age-related toxicity of adjuvantchemotherapy in women with breast cancer
Authors: Dees, EC O'Reilly, S Goodman, SN Sartorius, S Levine, MA Jones, RJ Grochow, LB Donehower, RC Fetting, JH
Citation: Ec. Dees et al., A prospective pharmacologic evaluation of age-related toxicity of adjuvantchemotherapy in women with breast cancer, CANCER INV, 18(6), 2000, pp. 521-529
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil
Authors: Baker, SD Diasio, RB O'Reilly, S Lucas, VS Khor, SP Sartorius, SE Donehower, RC Grochow, LB Spector, T Hohneker, JA Rowinsky, EK
Citation: Sd. Baker et al., Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil, J CL ONCOL, 18(4), 2000, pp. 915-926
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: Acceptable toxicity and suggestion of improved 1-year disease-free survival
Authors: Chakravarthy, A Abrams, RA Yeo, CJ Korman, LT Donehower, RC Hruban, RH Zahurek, ML Grochow, LB O'Reilly, S Hurwitz, H Jaffee, EM Lillemoe, KD Cameron, JL
Citation: A. Chakravarthy et al., Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: Acceptable toxicity and suggestion of improved 1-year disease-free survival, INT J RAD O, 48(4), 2000, pp. 1089-1096
HIV infection presenting as an unusually large pure yolk sac tumor of the testis
Authors: Munver, R Donehower, RC Kronz, JD Polascik, TJ
Citation: R. Munver et al., HIV infection presenting as an unusually large pure yolk sac tumor of the testis, J UROL, 164(5), 2000, pp. 1653-1654
Absorption, metabolism, and excretion of C-14-temozolomide following oral administration to patients with advanced cancer
Authors: Baker, SD Wirth, M Statkevich, P Reidenberg, P Alton, K Sartorius, SE Dugan, M Cutler, D Batra, V Grochow, LB Donehower, RC Rowinsky, EK
Citation: Sd. Baker et al., Absorption, metabolism, and excretion of C-14-temozolomide following oral administration to patients with advanced cancer, CLIN CANC R, 5(2), 1999, pp. 309-317
Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors
Authors: Nelson, JB Chen, RN Bishoff, JT Oh, WK Kantoff, PW Donehower, RC Kavoussi, LR
Citation: Jb. Nelson et al., Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors, UROLOGY, 54(6), 1999, pp. 1064-1067
Long term follow-up of women treated with 16-week, dose-intensive adjuvantchemotherapy for high risk breast carcinoma
Authors: Mikhak, B Zahurak, M Abeloff, MD Fetting, JH Davidson, NE Donehower, RC Waterfield, W Kennedy, MJ
Citation: B. Mikhak et al., Long term follow-up of women treated with 16-week, dose-intensive adjuvantchemotherapy for high risk breast carcinoma, CANCER, 85(4), 1999, pp. 899-904
Risultati: 1-17 |